Drug Interactions between moexipril and silodosin
This report displays the potential drug interactions for the following 2 drugs:
- moexipril
- silodosin
Interactions between your drugs
moexipril silodosin
Applies to: moexipril and silodosin
MONITOR: Additive hypotensive effects may occur when ACE inhibitors are used in combination with alpha-blockers. In the presence of ACE inhibition, the risk and/or severity of first-dose effects associated with alpha-blockers such as postural hypotension and syncope may be increased. In a study of six healthy subjects, mean blood pressure (systolic/diastolic) declined by 27/28 mmHg and 19/22 mmHg when a single 2 mg dose of bunazosin was given one hour after enalapril 10 mg and 2.5 mg, respectively, compared to a 9.5/6.7 mmHg decrease following bunazosin 2 mg or enalapril 10 mg alone. Potentiation of first-dose response has also been reported with prazosin administered in the presence of enalapril.
MANAGEMENT: Caution is advised during coadministration of these agents, particularly when initiating an alpha-blocker in the presence of an ACE inhibitor. Small initial dosages of the alpha-blocker should be considered and gradually titrated to desired effect, while the ACE inhibitor dosage may also need to be reduced. Hemodynamic responses should be monitored, especially during the first few weeks of therapy. Taking the alpha-blocker at bedtime may minimize the occurrence of orthostatic effects. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.
References (2)
- Baba T, Tomiyama T, Takebe K (1990) "Enhancement by an ACE inhibitor of first-dose hypotension caused by an alpha-blocker." N Engl J Med, 322, p. 1237
- (2002) "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc
Drug and food interactions
moexipril food
Applies to: moexipril
GENERALLY AVOID: Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors. In some cases, affected patients were using a potassium-rich salt substitute. ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.
MANAGEMENT: It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake. Particular attention should be paid to the potassium content of salt substitutes.
References (3)
- (2002) "Product Information. Vasotec (enalapril)." Merck & Co., Inc
- Good CB, McDermott L (1995) "Diet and serum potassium in patients on ACE inhibitors." JAMA, 274, p. 538
- Ray K, Dorman S, Watson R (1999) "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens, 13, p. 717-20
silodosin food
Applies to: silodosin
ADJUST DOSING INTERVAL: Food may reduce the oral bioavailability of silodosin. The effect of a moderate-fat, moderate-calorie meal on silodosin pharmacokinetics was variable and decreased silodosin maximum plasma concentration (Cmax) by approximately 18% to 43% and systemic exposure (AUC) by 4% to 49% across three different studies. The maximum effect of food (i.e., coadministration with a high-fat, high-calorie meal) on the pharmacokinetics of silodosin was not evaluated. Safety and efficacy clinical trials for silodosin were always conducted in the presence of food intake.
MANAGEMENT: Patients should be instructed to take silodosin with a meal to reduce the risk of adverse events.
References (1)
- (2008) "Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.